P

Pulike Biological Engineering Inc
SSE:603566

Watchlist Manager
Pulike Biological Engineering Inc
SSE:603566
Watchlist
Price: 13.35 CNY -0.6% Market Closed
Market Cap: 4.6B CNY
Have any thoughts about
Pulike Biological Engineering Inc?
Write Note

Pulike Biological Engineering Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pulike Biological Engineering Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
P
Pulike Biological Engineering Inc
SSE:603566
Interest Income Expense
ÂĄ13m
CAGR 3-Years
-30%
CAGR 5-Years
24%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Interest Income Expense
ÂĄ1.1B
CAGR 3-Years
52%
CAGR 5-Years
82%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Interest Income Expense
ÂĄ145.3m
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
23%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Interest Income Expense
ÂĄ472.8m
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
21%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Interest Income Expense
ÂĄ958.5m
CAGR 3-Years
-5%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Interest Income Expense
-ÂĄ20.1m
CAGR 3-Years
-107%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pulike Biological Engineering Inc
Glance View

Market Cap
4.6B CNY
Industry
Pharmaceuticals

Pulike Biological Engineering, Inc. engages in the research, development, manufacturing and sale of biological products for animals, chemical drugs and Chinese veterinary drugs. The company is headquartered in Luoyang, Henan and currently employs 1,809 full-time employees. The company went IPO on 2015-05-18. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The firm's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.

Intrinsic Value
21.21 CNY
Undervaluation 37%
Intrinsic Value
Price
P

See Also

What is Pulike Biological Engineering Inc's Interest Income Expense?
Interest Income Expense
13m CNY

Based on the financial report for Sep 30, 2024, Pulike Biological Engineering Inc's Interest Income Expense amounts to 13m CNY.

What is Pulike Biological Engineering Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
24%

The average annual Interest Income Expense growth rates for Pulike Biological Engineering Inc have been -30% over the past three years , 24% over the past five years .

Back to Top